Safeguard Scientifics Announces Fourth Quarter And Full-Year 2019 Financial Results

RADNOR, Pa., Feb. 27, 2020 /PRNewswire/ -- Safeguard Scientifics, Inc. (NYSE:SFE) ("Safeguard" or the "Company") today announced financial results for the three months and 12 months ended December 31, 2019.

Highlights

    --  Safeguard has returned over $187 million to our balance sheet since we
        began our new strategic direction in 2018 (including over $104 million
        in 2019) and we continue the pursuit of additional exits from our
        various company interests in an aggressive, but patient and rational
        manner.
    --  During 2019 the Company fully repaid its outstanding debt and paid a
        $1.00 per share return of capital dividend.
    --  At December 31, 2019, the Company's balance of cash, cash equivalents
        and restricted cash totaled $25.0 million.
    --  We committed to return value to our shareholders whenever we have in
        excess of a prudent minimum of liquidity.  Presently, our Board has
        determined that minimum to be $25 million.  When we exceed that level we
        intend to return value to shareholders in the form of either share
        repurchases and/or dividends.
    --  Safeguard continues to prudently manage follow-on deployments to its
        ownership interests.  Follow-on fundings totaled $2.2 million and $16.7
        million for the three months and year ended December 31, 2019,
        respectively, in line with the expectations we established at the
        beginning of the year.
    --  General and administrative expenses continued to decrease, totaling $2.1
        million for the three months ended December 31, 2019 as compared to $2.6
        million for the comparable prior year quarter, and totaling $10.0
        million for the year ended December 31, 2019 as compared to $16.9
        million for 2018.
    --  Corporate expenses totaled $1.4 million and $7.1 million for the three
        months and year ended December 31, 2019, respectively, a substantial
        decline from $1.9 million and $9.9 million for the comparable prior year
        periods and well below the less than $8 million expectation established
        at the beginning of the year.  Corporate expenses are general and
        administrative expenses excluding depreciation, severance, stock based
        compensation and other non-recurring items.
    --  Our Board of Directors is now compensated solely with Safeguard equity
        and the size of the Board will be reduced to four from six directors at
        the Company's upcoming annual meeting.

"We are pleased with what we accomplished in 2019. The most significant milestone we accomplished in 2019 was the $1.00 per share return of capital dividend we paid in December," said Brian J. Sisko, Safeguard's President and CEO. "Most importantly, we continue to hold a valuable portfolio of ownership interests representing $230 million of deployed capital in 15 tech-enabled companies and all other ownership interests. The companies continue to mature and we are well-positioned to capitalize on exit opportunities that will create value for our shareholders. We remain on course with the timetable we outlined at the outset of our current strategy."

For the year ended December 31, 2019, the Company's net income was $54.6 million, or $2.64 per share, compared with a net loss of $15.6 million, or $0.76 per share, in 2018. For the three months ended December 31, 2019, Safeguard's net loss was $0.7 million, or $0.03 per share, compared with a net loss of $16.6 million, or $0.81 per share, for the same period in 2018.

OUTLOOK
"Now that all of our debt has been repaid, and given our current liquidity position, virtually all proceeds from monetization events will be available for return of value to our shareholders" said Mark A. Herndon, Safeguard's Senior Vice President and Chief Financial Officer. "We will judiciously make deployments to protect our existing ownership interests as and where appropriate." Corporate expenses for the year ended December 31, 2020 are forecasted to continue to decline and are expected to range from $6.4 to $6.8 million as compared to $7.1 million for the year ended December 31, 2019. Follow-on funding requirements for the full year of 2020 are forecasted to be between $5 and $10 million.

AGGREGATE COMPANY REVENUE
Aggregate annual revenue for 2019 for Safeguard's 15 remaining ownership interests, which were formerly referred to as partner companies, was $357 million. Aggregate revenue for the same companies was $330 million for 2018, representing revenue growth of 8% for the entire portfolio. Excluding our digital media companies, the aggregate year-over-year revenue of Safeguard's remaining portfolio of ownership interests grew at 41%. Note that revenue from "Other Ownership Interests" in the table below are excluded from this total.

OWNERSHIP INTERESTS AT DECEMBER 31, 2019



       
              Companies                                       
            
              Category 
     
          Acquisition   Primary  
     
             Carrying      Cost
                                                                                                    Year             Ownership%     Value
                                                                                                                                                            (in
                                                                                                                                                        millions)
                                                                                                                                          (in millions)

    ---                                                                                                                                                       ---




       
              Initial Revenue Stage:  Up to $1 million in revenue



          None



       
              Expansion Stage:  $1 million to $5 million in revenue



       Moxe Health Corporation *                                  
            Healthcare                          2016      29.9%                    $5.4        $7.5



       
              Traction Stage:  $5 million to $10 million in revenue



       InfoBionic, Inc. *                                         
            Healthcare                          2014      25.2%                               22.0



       meQuilibrium *                                             
            Healthcare                          2015      32.7%                     3.8        13.0



       Trice Medical, Inc.+ *                                     
            Healthcare                          2014      16.6%                     2.0        10.2



       Zipnosis, Inc.+ *                                          
            Healthcare                          2015      37.7%                     3.1        10.0



       Sonobi, Inc.                                               
            Digital Media                       2015      21.6%                     8.0        13.4



       QuanticMind, Inc.                                          
            Digital Media                       2015      24.2%                     5.1        13.5



       WebLinc, Inc.                                              
            Digital Media                       2014      38.5%                     5.9        16.1



       Lumesis, Inc.                                              
            Financial Services                  2012      43.5%                     0.6         6.3



       
              High Traction Stage:  $10 million to $15 million in revenue



       Clutch Holdings, Inc.                                      
            Digital Media                       2013      41.2%                     5.5        16.6



       Prognos Health, Inc.                                       
            Healthcare                          2011      28.7%                     4.8        12.6



       
              Greater than $15 million in revenue



       Aktana, Inc.+ *                                            
            Healthcare                          2016      17.8%                     3.5        11.7



       Syapse, Inc.*                                              
            Healthcare                          2014      20.0%                     1.6        20.6



       Flashtalking                                               
            Digital Media                       2018      10.1%                    11.0        19.2



       MediaMath, Inc.                                            
            Digital Media                       2009      13.3%                               15.5



       
              Other Ownership Interests



       T-REX Group                                                
            Financial Services                  2016                                6.0         6.0



       Velano Vascular                                            
            Healthcare                          2013                                3.1         1.7



       All others                                                 
            Various                                                                7.7        14.3


                                                                                                                      TOTAL:                   $77.1      $230.2

(+) Company progressed into higher revenue stage this quarter.
* Company progressed into higher revenue stage this year.

CONFERENCE CALL AND WEBCAST DETAILS

Please call 10-15 minutes prior to the call to register.

Date: Thursday, February 27, 2020

Time: 9:00 am ET

Webcast: www.safeguard.com/events

Live Number: 833-236-5756 // (International) 647-689-4184

Replay Number: 800-585-8367 // (International) 416-621-4642

Access Code: 1495918

Speakers: President and Chief Executive Officer, Brian J. Sisko; and Senior Vice President and Chief Financial Officer, Mark A. Herndon

Format: Discussion of fourth quarter and full-year 2019 financial results followed by Q&A

Replay will be available through March 27, 2020 at 11:59 pm ET. For more information please contact IR@safeguard.com.

About Safeguard Scientifics
Historically, Safeguard Scientifics (NYSE:SFE) has provided capital and relevant expertise to fuel the growth of technology-driven businesses. Safeguard has a distinguished track record of fostering innovation and building market leaders that spans more than six decades. For more information, please visit www.safeguard.com.

Forward-looking Statements
Except for the historical information and discussions contained herein, statements contained in this release may constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Our forward-looking statements are subject to risks and uncertainties. Forward-looking statements include, but are not limited to, statements regarding Safeguard's initiatives taken or contemplated to enhance and unlock value for all of its shareholders, Safeguard's efforts to execute on and implement its strategy to streamline its organizational structure, reduce its operating costs, pursue monetization opportunities for ownership interests and maximize the return of value to its shareholders, Safeguard's ability to create, unlock, enhance and maximize shareholder value, the effect of Safeguard's management succession plan on driving increased organizational effectiveness and efficiencies, the ability of the management team to execute Safeguard's strategy, the availability of, the timing of, and the proceeds that may ultimately be derived from the monetization of ownership interests, Safeguard's projections regarding the reduction in its ongoing operating expenses, Safeguard's projections regarding annualized operating expenses and expected severance expenses, monetization opportunities for ownership interests, and the amount of net proceeds from the monetization of ownership interests that will enable the return of value to Safeguard shareholders after satisfying working capital needs and the timing of such return of value. Such forward-looking statements are not guarantees of future operational or financial performance and are based on current expectations that involve a number of uncertainties, risks and assumptions that are difficult to predict. Therefore, actual outcomes and/or results may differ materially from those expressed or implied by such forward-looking statements. The risks and uncertainties that could cause actual results to differ materially include, among others, our ability to make good decisions about the monetization of our ownership interests for maximum value or at all and the return of value to our shareholders, our ability to successfully execute on our strategy to streamline our organizational structure and align our cost structure to increase shareholder value, whether our strategy will better position us to focus our resources on the highest-return opportunities and deliver enhanced shareholder value, the ongoing support of our existing ownership interests, the fact that our ownership interests may vary from period to period, challenges to achieving liquidity from our ownership interests, fluctuations in the market prices of any publicly traded holdings, if any, competition, our inability to obtain maximum value for our ownership interests, our ability to attract and retain qualified employees, market valuations in sectors in which our ownership interests operate, our inability to control our ownership interests, our need to manage our assets to avoid registration under the Investment Company Act of 1940, risks, disruption, costs and uncertainty caused by or related to the actions of activist shareholders, including that if individuals are elected to our Board with a specific agenda, it may adversely affect our ability to effectively implement our business strategy and create value for our shareholders and perceived uncertainties as to our future direction as a result of potential changes to the composition of our Board may lead to the perception of a change in the direction of our business, instability or a lack of continuity that may adversely affect our business, and risks associated with our ownership interests, including the fact that most of our ownership interests have a limited operating history and a history of operating losses, face intense competition and may never be profitable, the effect of economic conditions in the business sectors in which Safeguard's ownership interests operate, and other uncertainties described in our filings with the Securities and Exchange Commission. Many of these factors are beyond the Company's ability to predict or control. As a result of these and other factors, the Company's past operational and financial performance should not be relied on as an indication of future performance. The Company does not assume any obligation to update any forward-looking statements or other information contained in this press release.

SAFEGUARD CONTACT:
John E. Shave III, IRC
Safeguard Investor Relations
(610) 975-4952
jshave@safeguard.com


                                                                          
        
           Safeguard Scientifics, Inc.


                                                                        
       
         Condensed Consolidated Balance Sheets


                                                                             
       
                (in thousands)




                                                                                                                                  December 31, 2019         December 31, 2018








     
                Assets



     Cash, cash equivalents, restricted cash and marketable securities                                                          $
              25,053                       $
       46,158



     Other current assets                                                                                                1,297                         577




       Total current assets                                                                                             26,350                      46,735



     Ownership interests in and advances                                                                                77,129                      95,585



     Other assets                                                                                                        4,098                       3,417



     
                Total Assets                                                                                                 $
              107,577                      $
       145,737






     
                Liabilities and Equity



     Other current liabilities                                                                                                   $
              2,429              5,780



     Credit facility - current                                                                                                                     22,100



     Credit facility repayment feature                                                                                                              5,060




       Total current liabilities                                                                                         2,429                      32,940



     Credit facility - non-current                                                                                                                 43,014



     Lease liability - non-current                                                                                       2,380



     Other long-term liabilities                                                                                         1,027                       2,804



     Total equity                                                                                                      101,741                      66,979



     
                Total Liabilities and Equity                                                                                 $
              107,577                      $
       145,737


                                                         
            
                Safeguard Scientifics, Inc.


                                                
             
              Condensed Consolidated Statements of Operations


                                                   
              
              (in thousands, except per share amounts)




                                                         
            Three Months Ended                               
            Twelve Months Ended
                                                                December 31,                                               December 31,


                                                     2019                            2018                      2019                              2018






     Operating expenses                                     $
            2,060                                            $
            2,618                  $
          9,982      $
         16,871




     Operating loss                              (2,060)                                    (2,618)                                       (9,982)          (16,871)





     Other income (loss), net                      2,245                                       (193)                                        12,255            (5,158)



     Interest, net                                   174                                     (6,021)                                      (11,979)          (13,261)



     Equity income (loss), net                   (1,057)                                    (7,791)                                        64,267             19,661






     Net income (loss) before income taxes         (698)                                   (16,623)                                        54,561           (15,629)



     Income tax benefit (expense)




     Net income (loss)                                      $
            (698)                                        $
            (16,623)                $
          54,561    $
         (15,629)






     Net income (loss) per share:



     Basic                                                 $
            (0.03)                                          $
            (0.81)                  $
          2.64      $
         (0.76)




     Diluted                                               $
            (0.03)                                          $
            (0.81)                  $
          2.64      $
         (0.76)






     Weighted average shares used in computing


     income (loss) per share:



     Basic                                        20,674                                      20,568                                         20,636             20,544



     Diluted                                      20,674                                      20,568                                         20,636             20,544


                                    
              
                Safeguard Scientifics, Inc.


                                  
              
                Partner Company Financial Data


                                          
              
                (in thousands)





       
                
                  Additional Financial Information

    ---



                                     Non-
                                     GAAP
                                     Measures

    ---

        In discussing financial results and guidance, the Company refers
         to the measure "corporate costs" which is not in accordance with
         Generally Accepted Accounting Principles (GAAP).  We use this
         non-GAAP financial measure internally to make operating and
         strategic decisions, including evaluating our overall
         performance and as a factor in determining compensation for
         certain employees.  We have defined corporate expenses as
         general and administrative costs excluding Depreciation, Stock
         based compensation, severance and retirement costs, and non-
         recurring items and other.  Non-recurring items and other in
         2019 includes accruals related to the Company's LTIP plan that



     
                Corporate expenses reconciliation:


                                                      
            Three Months Ended                    
          Twelve Months Ended
                                                             December 31,                                  December 31,


                                                        2019                      2018                 2019                 2018




      Corporate expenses                                    $
              1,404              $
     1,894                             $
     7,118   $
      9,854





      Depreciation                                                                    485                                 808        692



      Stock based compensation                          303                            113                               1,237        966



      Severance and retirement costs                     32                            126                                 248      3,942



      Non-recurring items and other                     321                                                               571      1,417



      General and administrative costs                      $
              2,060              $
     2,618                             $
     9,982  $
      16,871

View original content to download multimedia:http://www.prnewswire.com/news-releases/safeguard-scientifics-announces-fourth-quarter-and-full-year-2019-financial-results-301012235.html

SOURCE Safeguard Scientifics, Inc.